Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial

Alan P. Venook*, Donna Niedzwiecki, Heinz Josef Lenz, Federico Innocenti, Briant Fruth, Jeffrey A. Meyerhardt, Deborah Schrag, Claire Greene, Bert H. O'Neil, James Norman Atkins, Scott Berry, Blase N. Polite, Eileen M. O'Reilly, Richard M. Goldberg, Howard S. Hochster, Richard L. Schilsky, Monica M. Bertagnolli, Anthony B. El-Khoueiry, Peter Watson, Al B. BensonDaniel L. Mulkerin, Robert J. Mayer, Charles Blanke

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

389 Scopus citations

Fingerprint

Dive into the research topics of 'Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial'. Together they form a unique fingerprint.

Medicine & Life Sciences